Skip to main content

Vor Biopharma, Inc. (VOR)

NASDAQ: VOR · IEX Real-Time Price · USD
12.00 -0.48 (-3.85%)
Nov 26, 2021 1:00 PM EST - Market closed

Company Description

Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.

It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies.

The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma, Inc.
CountryUnited States
Founded2015
IPO DateFeb 5, 2021
IndustryBiotechnology
SectorHealthcare
Employees122

Contact Details

Address:
100 Cambridgepark Drive
Cambridge, MA 02140
United States
Phone617 655 6580
Websitevorbiopharma.com

Stock Details

Ticker SymbolVOR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code1817229

Key Executives

NamePosition
Dr. Robert Ang M.B.A., M.D., MBBSPresident, Chief Executive Officer and Director
Dr. Tirtha Chakraborty Ph.D.Chief Scientific Officer
Dr. Christopher Slapak M.D.Chief Medical Officer
Dr. Siddhartha Mukherjee DPHIL, M.D.Scientific Founder and Chairman of Scientific Advisory Board
Dr. Nathan D. Jorgensen M.B.A., Ph.D.Chief Financial Officer
Dr. Sadik Kassim Ph.D.Chief Technology Officer
Amy Mendel J.D.Chief Legal Officer and Secretary
Tania PhilippChief People Officer
Dr. Robert G. Pietrusko Pharm.D., Pharm. D.Chief Regulatory and Quality Officer
John C. KingChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Nov 18, 20214Statement of changes in beneficial ownership of securities
Nov 18, 20214Statement of changes in beneficial ownership of securities
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 19, 20214Statement of changes in beneficial ownership of securities
Aug 9, 202110-QQuarterly report [Sections 13 or 15(d)]
Jun 17, 20218-KCurrent report
May 6, 202110-QQuarterly report [Sections 13 or 15(d)]
Apr 5, 20214Statement of changes in beneficial ownership of securities
Mar 25, 202110-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 10, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings